Summary
8EM Chart
Top 3 Genomics Stocks to Consider for Your Portfolio
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.75 per share a year ago.
Editas Medicine Inc. (8EM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Editas Medicine Inc. ever had a stock split?
Editas Medicine Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gilmore O'Neill CEO | XFRA Exchange | US28106W1036 ISIN |
| US Country | 246 Employees | - Last Dividend | - Last Split | 3 Feb 2016 IPO Date |
Overview
Editas Medicine, Inc. is a trailblazer in the emerging field of genome editing, signifying its pivotal role in ushering in a new era of genomic medicine aimed at confronting severe diseases head-on. Established on the cutting-edge CRISPR technology, this company stands out in its commitment to leverage gene editing for the creation of groundbreaking medical treatments. It embarked on its mission under the name Gengine, Inc. before transitioning to Editas Medicine, Inc. in November 2013, marking a new chapter in its quest to redefine medical treatment through genetic innovation. Based in the innovation hub of Cambridge, Massachusetts, Editas Medicine, Inc. is intensely involved in clinical-stage research and development, striving to transform the landscape of medical therapeutics through its dedication to scientific excellence and patient-centered care.
Products and Services
- EDIT-101
A pioneering product in Phase 1/2 BRILLIANCE trial, EDIT-101 targets Leber Congenital Amaurosis, aiming to offer a significant leap forward in treating this genetic disorder. This product exemplifies Editas Medicine's innovative use of CRISPR technology for direct, transformative medical interventions.
- Reni-cel
Also known as a gene-edited medicine in clinical development, reni-cel holds the promise for treating sickle cell disease and transfusion-dependent beta-thalassemia. By addressing the genetic roots of these conditions, reni-cel represents a new horizon in therapeutic strategies for blood disorders.
- Alpha-beta T Cells
These are being developed for the treatment of solid and liquid tumors, representing a novel approach in the fight against cancer. Through the engineering of T cells, Editas aims to harness the body's immune system to target and eliminate cancerous cells, highlighting the therapeutic potential of gene editing in oncology.
- Gamma Delta T Cell Therapies
Focused on cancer treatment, these therapies are part of Editas Medicine’s broader strategy to develop innovative cancer treatments through the manipulation of the immune system. Gamma delta T cell therapies represent a cutting-edge direction in immunotherapy, aimed at overcoming some of the toughest challenges in cancer care.
